Jean O'COnnell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jean O'COnnell has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Donal O'SHea
Obesity Immunology Research, St Vincent's University Hospital and University College Dublin, Dublin 4, Ireland
2 shared publications - Lydia Lynch
Department of Endocrinology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
2 shared publications A. Hogan
1 shared publicationAiden McCormick
Liver Transplant Unit, St Vincent's University Hospital, Dublin, Ireland
1 shared publicationAnna Kwasnik
Obesity Research Group, Education and Research Centre, St Vincent's University Hospital, Dublin, Ireland
1 shared publication- Cliona O'FArrelly
School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, D02R590, Ireland
1 shared publication
Latest Publications
- 11 June 2014
- Published by Springer Nature in Current Diabetes Reports
- Vol. 14 (8) , 1-10
Cystic Fibrosis Related Diabetes
Improved life expectancy in cystic fibrosis (CF) has led to an expanding population of adults with CF, now representing almost 50 % of the total CF population. This creates new challenges from long-term complications such as diabetes mellitus (DM), a condition that is present in 40 %–50 % of adults with CF. Cystic fibrosis-related diabetes (CFRD) results from a primary defect of insulin deficiency and although sharing features with type 1 (DM1) and type 2 diabetes (DM2), it is a clinically distinct condition. Progression to diabetes is associated with poorer CF clinical outcomes and increased mortality. CFRD is not associated with an increased risk of cardiovascular disease and the prevalence of microvascular complications is lower than DM1 or DM2. Rather, the primary goal of insulin therapy is the preservation of lung function and optimization of nutritional status. There is increasing evidence that appropriate screening and early intervention with insulin can reverse weight loss and improve pulmonary function. This approach may include targeting postprandial hyperglycemia not detected by standard diagnostic tests such as the oral glucose tolerance test. Further clinical research is required to guide when and how much to intervene in patients who are already dealing with the burden of one chronic illness.
- 11 June 2014
- Published by Springer Nature in Current Diabetes Reports
- Vol. 14 (8) , 1-10
Cystic Fibrosis Related Diabetes
Improved life expectancy in cystic fibrosis (CF) has led to an expanding population of adults with CF, now representing almost 50 % of the total CF population. This creates new challenges from long-term complications such as diabetes mellitus (DM), a condition that is present in 40 %–50 % of adults with CF. Cystic fibrosis-related diabetes (CFRD) results from a primary defect of insulin deficiency and although sharing features with type 1 (DM1) and type 2 diabetes (DM2), it is a clinically distinct condition. Progression to diabetes is associated with poorer CF clinical outcomes and increased mortality. CFRD is not associated with an increased risk of cardiovascular disease and the prevalence of microvascular complications is lower than DM1 or DM2. Rather, the primary goal of insulin therapy is the preservation of lung function and optimization of nutritional status. There is increasing evidence that appropriate screening and early intervention with insulin can reverse weight loss and improve pulmonary function. This approach may include targeting postprandial hyperglycemia not detected by standard diagnostic tests such as the oral glucose tolerance test. Further clinical research is required to guide when and how much to intervene in patients who are already dealing with the burden of one chronic illness.
- 1 April 2011
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 96 (4) , E680-E684
Preadipocyte Factor-1 Is Associated with Metabolic Profile in Severe Obesity
Dysfunctional adipose tissue has been proposed as a key pathological process linking obesity and metabolic disease. Preadipocyte factor-1 (Pref-1) has been shown to inhibit differentiation in adipocyte precursor cells and could thereby play a role in determining adipocyte size, adipose tissue functioning, and metabolic profile in obese individuals. We hypothesized that adipose tissue from metabolically healthy obese (MHO) and matched metabolically unhealthy obese individuals would demonstrate distinct differences in relation to Pref-1 expression, adipocyte size, and inflammatory markers. This was a cross-sectional study, investigating obese patients undergoing bariatric surgery at a tertiary referral centre. Patients included 12 MHO and 17 age- and body mass index-matched metabolically unhealthy obese individuals. Pref-1, monocyte chemotactic protein-1, TNF-α, granulocyte colony-stimulating factor, IL-6, and adiponectin levels, macrophage numbers, and adipocyte size were measured in omental and subcutaneous adipose tissue. The MHO group had a lower level of Pref-1 (per 1000 adipocytes) in both subcutaneous [160 (136-177) versus 194 (153-355); P < 0.05] and omental adipose tissue [102 (32-175) versus 194 (100-350); P < 0.005]. This was associated with lower numbers of macrophages, lower levels of TNF-α, monocyte chemotactic protein-1, and granulocyte colony-stimulating factor, and higher levels of adiponectin. Omental Pref-1 showed strong correlations with adipocyte size (r = 0.67, P < 0.0005) and metabolic and adipokine parameters, including percent fatty liver (r = 0.62, P < 0.005), fasting glucose (r = 0.68, P < 0.0005), triglyceride (r = 0.60, P < 0.005), high-density lipoprotein cholesterol (r = -0.46, P < 0.05), and adiponectin (r = -0.71, P < 0.05). Adipose tissue in MHO individuals had lower levels of Pref-1, a known inhibitor of preadipocyte differentiation, and a more favorable inflammatory profile. These factors may be key to protecting this subgroup of obese individuals from the adverse metabolic profile associated with excess adiposity.
- 1 April 2011
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 96 (4) , E680-E684
Preadipocyte Factor-1 Is Associated with Metabolic Profile in Severe Obesity
Dysfunctional adipose tissue has been proposed as a key pathological process linking obesity and metabolic disease. Preadipocyte factor-1 (Pref-1) has been shown to inhibit differentiation in adipocyte precursor cells and could thereby play a role in determining adipocyte size, adipose tissue functioning, and metabolic profile in obese individuals. We hypothesized that adipose tissue from metabolically healthy obese (MHO) and matched metabolically unhealthy obese individuals would demonstrate distinct differences in relation to Pref-1 expression, adipocyte size, and inflammatory markers. This was a cross-sectional study, investigating obese patients undergoing bariatric surgery at a tertiary referral centre. Patients included 12 MHO and 17 age- and body mass index-matched metabolically unhealthy obese individuals. Pref-1, monocyte chemotactic protein-1, TNF-α, granulocyte colony-stimulating factor, IL-6, and adiponectin levels, macrophage numbers, and adipocyte size were measured in omental and subcutaneous adipose tissue. The MHO group had a lower level of Pref-1 (per 1000 adipocytes) in both subcutaneous [160 (136-177) versus 194 (153-355); P < 0.05] and omental adipose tissue [102 (32-175) versus 194 (100-350); P < 0.005]. This was associated with lower numbers of macrophages, lower levels of TNF-α, monocyte chemotactic protein-1, and granulocyte colony-stimulating factor, and higher levels of adiponectin. Omental Pref-1 showed strong correlations with adipocyte size (r = 0.67, P < 0.0005) and metabolic and adipokine parameters, including percent fatty liver (r = 0.62, P < 0.005), fasting glucose (r = 0.68, P < 0.0005), triglyceride (r = 0.60, P < 0.005), high-density lipoprotein cholesterol (r = -0.46, P < 0.05), and adiponectin (r = -0.71, P < 0.05). Adipose tissue in MHO individuals had lower levels of Pref-1, a known inhibitor of preadipocyte differentiation, and a more favorable inflammatory profile. These factors may be key to protecting this subgroup of obese individuals from the adverse metabolic profile associated with excess adiposity.
- Open Access
- 1 April 2010
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (4) , e9997
The Relationship of Omental and Subcutaneous Adipocyte Size to Metabolic Disease in Severe Obesity
Several studies have reported the existence of a subgroup of obese individuals with normal metabolic profiles. It remains unclear what factors are responsible for this phenomenon. We proposed that adipocyte size might be a key factor in the protection of metabolically healthy obese (MHO) individuals from the adverse effects of obesity. Thirty-five patients undergoing bariatric surgery were classified as MHO (n = 15) or metabolically unhealthy obese (MUO, n = 20) according to cut-off points adapted from the International Diabetes Federation definition of the metabolic syndrome. Median body mass index (BMI) was 48 (range 40–71). There was a moderate correlation between omental adipocyte size and subcutaneous adipocyte size (r = 0.59, p<0.05). The MHO group had significantly lower mean omental adipocyte size (80.9±10.9 µm) when compared with metabolically unhealthy patients (100.0±7.6 µm, p<0.0001). Mean subcutaneous adipocyte size was similar between the two groups (104.1±8.5 µm versus 107.9±7.1 µm). Omental, but not subcutaneous adipocyte size, correlated with the degree of insulin resistance as measured by HOMA-IR (r = 0.73, p<0.0005), as well as other metabolic parameters including triglyceride/HDL-cholesterol ratio and HbA1c. Twenty-eight patients consented to liver biopsy. Of these, 46% had steatohepatitis and fibrosis. Fifty percent (including all the MHO patients) had steatosis only. Both omental and subcutaneous adipocyte size were significantly associated with the degree of steatosis (r = 0.66, p<0.0001 and r = 0.63, p<0.005 respectively). However, only omental adipocyte size was an independent predictor of the presence or absence of fibrosis. Metabolically healthy individuals are a distinct subgroup of the severely obese. Both subcutaneous and omental adipocyte size correlated positively with the degree of fatty liver, but only omental adipocyte size was related to metabolic health, and possibly progression from hepatic steatosis to fibrosis.
- 1 April 2010
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (4) , e9997
Open AccessThe Relationship of Omental and Subcutaneous Adipocyte Size to Metabolic Disease in Severe Obesity
Several studies have reported the existence of a subgroup of obese individuals with normal metabolic profiles. It remains unclear what factors are responsible for this phenomenon. We proposed that adipocyte size might be a key factor in the protection of metabolically healthy obese (MHO) individuals from the adverse effects of obesity. Thirty-five patients undergoing bariatric surgery were classified as MHO (n = 15) or metabolically unhealthy obese (MUO, n = 20) according to cut-off points adapted from the International Diabetes Federation definition of the metabolic syndrome. Median body mass index (BMI) was 48 (range 40–71). There was a moderate correlation between omental adipocyte size and subcutaneous adipocyte size (r = 0.59, p<0.05). The MHO group had significantly lower mean omental adipocyte size (80.9±10.9 µm) when compared with metabolically unhealthy patients (100.0±7.6 µm, p<0.0001). Mean subcutaneous adipocyte size was similar between the two groups (104.1±8.5 µm versus 107.9±7.1 µm). Omental, but not subcutaneous adipocyte size, correlated with the degree of insulin resistance as measured by HOMA-IR (r = 0.73, p<0.0005), as well as other metabolic parameters including triglyceride/HDL-cholesterol ratio and HbA1c. Twenty-eight patients consented to liver biopsy. Of these, 46% had steatohepatitis and fibrosis. Fifty percent (including all the MHO patients) had steatosis only. Both omental and subcutaneous adipocyte size were significantly associated with the degree of steatosis (r = 0.66, p<0.0001 and r = 0.63, p<0.005 respectively). However, only omental adipocyte size was an independent predictor of the presence or absence of fibrosis. Metabolically healthy individuals are a distinct subgroup of the severely obese. Both subcutaneous and omental adipocyte size correlated positively with the degree of fatty liver, but only omental adipocyte size was related to metabolic health, and possibly progression from hepatic steatosis to fibrosis.
- 26 January 2010
- Published by Cambridge University Press (CUP) in Public Health Nutrition
- Vol. 13 (7) , 1090-1098
BMI ≥ 50 kg/m2is associated with a younger age of onset of overweight and a high prevalence of adverse metabolic profiles
Objective: To study the demographic and clinical parameters of three different categories of obesity, with particular focus on a cohort of individuals with BMI ≥ 50 kg/m2, the fastest growing category of obesity.Design: Over 700 obese individuals were studied (186 with BMI = 30–39 kg/m2, 316 with BMI = 40–49 kg/m2and 290 with BMI ≥ 50 kg/m2).Results: Median BMI was 51 kg/m2for patients who reported onset of overweight before 15 years of age, 47 kg/m2for patients who reported onset between 15 and 30 years, and 42 kg/m2for patients who became overweight after 30 years of age. The BMI ≥ 50 kg/m2group was notably younger than the group with BMI = 30–39 kg/m2(44 (sd11) yearsv. 50 (sd15) years;P< 0·0001). Eighteen per cent of obese patients studied were considered metabolically healthy according to standard cut-off points for blood pressure, fasting glucose and lipid profiles. However, the proportion of metabolically healthy individuals was significantly higher in the BMI = 30–39 kg/m2group than in the BMI = 40–49 kg/m2and BMI ≥ 50 kg/m2groups (31 %v. 17 % and 12 % respectively;P< 0·05 andP< 0·005). When compared with people of similar age in the general population, individuals with BMI ≥ 50 kg/m2had lower rates of marriage (51 %v. 72 %) and a higher prevalence of unemployment (14 %v. 5 %).Conclusions: The current study suggests that the increasing prevalence of childhood obesity worldwide will lead to many more individuals achieving a higher BMI at a younger age. Furthermore, an earlier onset of overweight does not appear to prevent the adverse metabolic health outcomes associated with extreme obesity.
- 26 January 2010
- Published by Cambridge University Press (CUP) in Public Health Nutrition
- Vol. 13 (7) , 1090-1098
BMI ≥ 50 kg/m2is associated with a younger age of onset of overweight and a high prevalence of adverse metabolic profiles
Objective: To study the demographic and clinical parameters of three different categories of obesity, with particular focus on a cohort of individuals with BMI ≥ 50 kg/m2, the fastest growing category of obesity.Design: Over 700 obese individuals were studied (186 with BMI = 30–39 kg/m2, 316 with BMI = 40–49 kg/m2and 290 with BMI ≥ 50 kg/m2).Results: Median BMI was 51 kg/m2for patients who reported onset of overweight before 15 years of age, 47 kg/m2for patients who reported onset between 15 and 30 years, and 42 kg/m2for patients who became overweight after 30 years of age. The BMI ≥ 50 kg/m2group was notably younger than the group with BMI = 30–39 kg/m2(44 (sd11) yearsv. 50 (sd15) years;P< 0·0001). Eighteen per cent of obese patients studied were considered metabolically healthy according to standard cut-off points for blood pressure, fasting glucose and lipid profiles. However, the proportion of metabolically healthy individuals was significantly higher in the BMI = 30–39 kg/m2group than in the BMI = 40–49 kg/m2and BMI ≥ 50 kg/m2groups (31 %v. 17 % and 12 % respectively;P< 0·05 andP< 0·005). When compared with people of similar age in the general population, individuals with BMI ≥ 50 kg/m2had lower rates of marriage (51 %v. 72 %) and a higher prevalence of unemployment (14 %v. 5 %).Conclusions: The current study suggests that the increasing prevalence of childhood obesity worldwide will lead to many more individuals achieving a higher BMI at a younger age. Furthermore, an earlier onset of overweight does not appear to prevent the adverse metabolic health outcomes associated with extreme obesity.